Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatme ...

Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic canc ...

Summit Therapeutics Inc. is currently enrolling patients in the Harmoni-7 study, a multiregional Phase III clinical trial ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

An immunotherapy treatment could ‘change the world’ for newly diagnosed head and neck cancer patients, giving them an extra two-and-a-half years of life.

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

During a major phase III trial, pembrolizumab combined with standard treatment kept cancer at bay for an average of 60 months ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

In the primary analysis for Harmoni-2, ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, progression-free survival (PFS), achieving a hazard ...